Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.55 |
| ▸ | ACACB | O00763 | 7/20 | 0.50 |
| ▸ | ACE | P12821 | 3/20 | 0.48 |
| ▸ | MME | P08473 | 3/20 | 0.47 |
| ▸ | CPA1 | P15085 | 2/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.47 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.46 |
| ▸ | GNPAT | O15228 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7292657 | 1.00 | CTSS (0.56) | CTSSCTSKLMNAITGB3ITGA2B | |
| SCHEMBL5435245 | 1.00 | CTSS (0.56) | CTSSCTSKLMNAITGB3ITGA2B | |
| SCHEMBL22285669 | 0.85 | ITGB3 (0.52) | CTSSITGB3ITGA2BACACBACE | |
| SCHEMBL22285670 | 0.85 | ITGB3 (0.52) | CTSSITGB3ITGA2BACACBACE | |
| SCHEMBL6139160 | 0.85 | NLRP3 (0.58) | CTSSCTSKACACB | |
| SCHEMBL9258153 | 0.85 | MME (0.47) | ITGB3ITGA2BACEMMECPA1 | |
| SCHEMBL29855080 | 0.84 | LOXL2 (0.49) | ACEMMECPA1ACE2GPR34 | |
| SCHEMBL28357222 | 0.84 | LOXL2 (0.49) | ACEMMECPA1ACE2GPR34 | |
| Afalanine SCHEMBL27419332 | 0.83 | CTSS (0.69) | CTSSCTSKLMNAACEMME | |
| Afalanine SCHEMBL27419331 | 0.83 | CTSS (0.69) | CTSSCTSKLMNAACEMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244241-A1 | Resin Composition | NISSHINBO INDUSTRIES, INC. (JP) | 2007-10-18 | — | — | US | disclosed |
| US-7084250-B2 | Process for the preparation of acetyl-amidiniophenylalanyl-cyclohexylglycyl-pyridinioalaninamides | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-08-01 | — | — | US | disclosed |
| EP-1254159-B9 | PROCESS FOR THE PREPARATION OF ACETYL-AMIDINIOPHENYLALANYL-CYCLOHEXYLGLYCYL-PYRIDYLALANINAMIDES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-06-28 | — | — | EP | disclosed |
| EP-1254159-B1 | PROCESS FOR THE PREPARATION OF ACETYL-AMIDINIOPHENYLALANYL-CYCLOHEXYLGLYCYL-PYRIDYLALANINAMIDES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-05-10 | — | — | EP | disclosed |
| US-20040225109-A1 | Process for the preparation of acetyl-amidiniophenylalanyl-cyclohexylglycyl-pyridinioalaninamides | AVENTIS PHARMA DEUTSCHLAND GMBH | 2004-11-11 | — | — | US | disclosed |
| US-6759384-B1 | LOW MOLECULAR WEIGHT ANTICOAGULANTS WITHOUT SIDE EFFECTS; DERIVATIVES OF AT LEAST PROLINE, LEUCINE AND ARGININE SEQUENCE | AVENTIS PHARMACEUTICALS INC. | 2004-07-06 | — | — | US | disclosed |
| EP-0758341-B1 | FACTOR Xa INHIBITORS | AVENTIS PHARMA INC (US) | 2004-03-24 | — | — | EP | disclosed |
| EP-1384725-A2 | Factor Xa inhibitors | Aventis Pharmaceuticals, Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1254159-A2 | PROCESS FOR THE PREPARATION OF ACETYL-AMIDINIOPHENYLALANYL-CYCLOHEXYLGLYCYL-PYRIDINIOALANINAMIDES | Aventis Pharma Deutschland GmbH (DE) | 2002-11-06 | — | — | EP | disclosed |
| US-20010031858-A1 | Process for the preparation of acetyl-amidiniophenylalanyl-cyclohexylglycyl-pyridinioalaninamides | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2001-10-18 | — | — | US | disclosed |
| WO-2001055175-A2 | PROCESS FOR THE PREPARATION OF ACETYL-AMIDINIOPHENYLALANYL-CYCLOHEXYLGLYCYL-PYRIDINIOALANINAMIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-08-02 | — | — | WO | disclosed |
| EP-0723586-B1 | ENZYME AND ITS USE IN PREPARING (S)-PIPECOLIC ACID | DARWIN DISCOVERY LTD (GB) | 1999-12-22 | — | — | EP | disclosed |
| US-5849510-A | Factor Xa inhibitors | SELECTIDE CORPORATION (US) | 1998-12-15 | — | — | US | disclosed |
| EP-0758341-A1 | FACTOR Xa INHIBITORS | SELECTIDE CORPORATION (US) | 1997-02-19 | — | — | EP | disclosed |
| WO-1995029189-A1 | FACTOR Xa INHIBITORS | SELECTIDE CORPORATION (US) | 1995-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040225109-A1 | Process for the preparation of acetyl-amidiniophenylalanyl-cyclohexylglycyl-pyridinioalaninamides | SERPINC1, F12, F11 | CTSS 746/4885CTSK 1631/4885LMNA 923/4885 |
| US-20010031858-A1 | Process for the preparation of acetyl-amidiniophenylalanyl-cyclohexylglycyl-pyridinioalaninamides | SERPINC1, F12, F11 | CTSS 746/4885CTSK 1631/4885LMNA 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.